ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-OR088

Dulaglutide Treatment Is Associated with Less eGFR Decline and Greater Reduction in Albuminuria in Type 2 Diabetes and CKD Stages 3-4 (AWARD-7)

Session Information

Category: Diabetes

  • 502 Diabetes Mellitus and Obesity: Clinical


  • Tuttle, Katherine R., Providence Health Care, University of Washington School of Medicine, Spokane, Washington, United States
  • Lakshmanan, Mark C., Eli Lilly and Company, Indianapolis, Indiana, United States
  • Gross, Jorge L., Centro de Pesquisas em Diabetes, Porto Alegre, Rio Grande do Sul, Brazil
  • Rayner, Brian, Division of Nephrology and Hypertension, Groote Schuur Hospital and University of Cape Town, Cape Town, South Africa
  • Busch, Robert S., Albany Medical Center Division of Community Endocrinology, Albany, New York, United States
  • Woodward, Brad, Eli Lilly and Company, Indianapolis, Indiana, United States
  • Zimmermann, Alan G., Eli Lilly and Company, Indianapolis, Indiana, United States
  • Botros, Fady T., Eli Lilly and Company, Indianapolis, Indiana, United States

The AWARD-7 phase 3 trial compared weekly dulaglutide (DU 1.5 or 0.75 mg) to daily insulin glargine (IG), both with insulin lispro, in participants with type 2 diabetes (T2D) and chronic kidney disease (CKD) stages 3-4.


Baseline (BL) characteristics (N=576) were: estimated glomerular filtration rate (eGFR CKD-EPI): 38±13 mL/min/1.73m2 [mean±SD], urine albumin/creatinine ratio (UACR, mean [median]): 847.2 (209.3), age: 65±9 years, A1c: 8.6±1.0%, duration of T2D: 18±9 years.


After 52 weeks, mean eGFR was not statistically different from BL with DU 1.5 mg, while it decreased with DU 0.75 mg and IG; UACR decreased from BL with both DU doses (table). DU 1.5 mg vs IG differences were statistically significant in participants with UACR >300 mg/g. Both doses of DU were noninferior to IG for the change in A1c.


In participants with T2D and CKD stages 3-4, overall effects on eGFR and UACR were mainly driven by lesser eGFR decline and greater UACR reduction in the DU 1.5 mg group vs IG in participants with UACR >300 mg/g.

Table. Effects of DU and IG on eGFR and albuminuria after 52 weeks
Study GroupAll (N=576)UACR >300 mg/g (n=258)UACR ≤300 mg/g (n=317)
Δ eGFR, mL/min/1.73m2%Δ UACRΔ eGFR, mL/min/1.73m2%Δ UACRΔ eGFR, mL/min/1.73m2%Δ UACR
DU 1.5 mg (N=192)-1.1
(-2.4, 0.2)
(-35.1, -7.5)
(-5.4, -1.4)
(-43.0, -11.5)
(-2.0, 1.3)
(-24.0, 22.8)
DU 0.75 mg (N=190)-1.5*
(-2.8, -0.2)
(-33.1, -4.6)
(-7.1, -3.2)
(-29.0, 8.5)
(-1.4, 1.9)
(-33.6, 8.0)
IG (N=194)-2.9**
(-4.2, -1.6)
(-27.1, 3.9)
(-8.2, -4.4)
(-18.8, 23.4)
(-2.9, 0.4)
(-29.0, 14.4)

Data are change from BL least squares mean (95% confidence interval). *2-sided p<0.05 and **2-sided p<0.001 change from BL, #2-sided p<0.05 and ##2-sided p<0.001 vs IG


  • Commercial Support